Inclusion Criteria | |
Age ≥ 18 years | |
CRVO with CMO as determined by fluorescein angiography and duration of onset less than 12 months | |
BCVA of 17–70 ETDRS letters (20/40–20/400) | |
CMT ≥300 μm as measured by OCT | |
Absent relative afferent pupillary defect | |
Exclusion Criteria | |
Systemic | |
Uncontrolled blood pressure (≥180 mmHg systolic and 110 mmHg diastolic) | |
Chronic renal failure | |
Major surgery within 1 month of study entry | |
Previous systemic anti-VEGF treatment | |
Women of childbearing age not using adequate contraception and women who are breast feeding | |
Intercurrent severe disease such as septicaemia | |
Ocular | |
Glaucoma which is uncontrolled with IOP-lowering medications | |
Past history of severe steroid response with IOP ≥ 35 mmHg following steroid treatment | |
Loss of vision due to other causes (e.g. age-related macular degeneration, myopic macular degeneration) | |
BCVA of < 20/200 in the fellow eye | |
Argon laser photocoagulation within 3 months of study entry | |
Previous intraocular surgery within 6 months of study entry | |
Stroke or myocardial infarction less than 3 months prior to study entry | |
Any active periocular or ocular infection or inflammation at screening or baseline. | |
Subjects, who in the opinion of the Investigator, may not benefit from treatment due to pre-existing or current macular condition (eg, vitreomacular traction, epiretinal membrane, scar, foveal atrophy) |